Workflow
2 Stocks That Turned $1,000 Into More Than $8,000 in 10 Years to Buy and Hold

Group 1: Market Overview - The average stock market return over the past few decades is around 10%, making broader equities competitive compared to other asset classes [1] - Investing in companies with market-beating potential is key, particularly those with a history of outperforming the market [1] Group 2: Intuitive Surgical - Intuitive Surgical has achieved a compound annual growth rate (CAGR) of 26.1% over the past 10 years, turning an initial investment of $1,000 into $10,140, compared to $3,320 for the S&P 500 [4] - The company is the leader in the robotic-assisted surgery (RAS) market, primarily driven by its da Vinci system, which is approved for various surgical procedures [5][6] - Intuitive Surgical has a first-mover advantage with an installed base of 10,189 da Vinci systems, reflecting a 15% year-over-year increase [8] - The aging global population is expected to increase surgical procedure volumes, benefiting Intuitive Surgical's growth prospects [10] Group 3: Competitive Landscape for Intuitive Surgical - Competition is increasing with Medtronic and Johnson & Johnson entering the RAS market, but Intuitive Surgical may still deliver market-beating returns [7] - High switching costs for healthcare facilities favor Intuitive Surgical, as they prefer to stick with their initial choice of equipment due to training and repair services [9] Group 4: Veeva Systems - Veeva Systems has achieved a CAGR of 24.2% over the past decade, turning an initial investment of $1,000 into $8,734 [11] - The company focuses on providing cloud-based services specifically for the healthcare industry, which has unique demands and regulatory constraints [12] - Veeva Systems benefits from high switching costs, as clients rely on its services for daily operations and regulatory compliance [14] - The total addressable market (TAM) for Veeva Systems is estimated at $20 billion, of which it has captured about 14%, with continued growth expected in the life sciences sector [15]